Clinical StudyEfficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial
Keywords
Cited by (0)
FDA device/drug status: Investigational (Novosis, E. coli-derived rhBMP-2).
Author disclosures: JHC: Grant: CG Bio/BioAlpha Inc (E, Paid directly to institution), pertaining to the submitted work. JHL: Grant: Bio alph (D, Paid directly to institution), pertaining to the submitted work; Stock Ownership: Bio alpha (D), outside the submitted work. JSY: Grant: CG Bio/BioAlpha Inc (D, Paid directly to institution), pertaining to the submitted work. BSC: Grant: CG Bio/BioAlpha Inc (E, Paid directly to institution), pertaining to the submitted work. JJY: Nothing to disclose. KHK: Grant: CG Bio/BioAlpha Inc (D, Paid directly to institution), pertaining to the submitted work. CJH: Grant: CG Bio/BioAlpha Inc (E, Paid directly to institution), pertaining to the submitted work. KBL: Grant: Bio alph (E, Paid directly to institution), pertaining to the submitted work. HJK: Nothing to disclose. CKL: Grant: CG Bio/BioAlpha Inc (D, Paid directly to institution), pertaining to the submitted work. HK: Nothing to disclose. KSS: Grant: Bio alpha (D, Paid directly to institution), pertaining to the submitted work. WDN: Grant: Bio alph (E, Paid directly to institution), pertaining to the submitted work. JH: Nothing to disclose.
The disclosure key can be found on the Table of Contents and at www.TheSpineJournalOnline.com.